Previous Close | 6.24 |
Open | 6.24 |
Bid | 5.93 x 400 |
Ask | 6.05 x 400 |
Day's Range | 5.96 - 6.49 |
52 Week Range | 1.57 - 8.19 |
Volume | |
Avg. Volume | 199,872 |
Market Cap | 260.951M |
Beta (5Y Monthly) | 0.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.05 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.50 |
Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that an abstract providing an upd
First Data Demonstrating Application of PREDATOR™ Platform in Immune-Mediated Diseases WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced a poster presenting preclinical data characterizing conditionally-activated IL-10 INDUKINE molecules for the treatment of colitis in animal models, a novel approach leveraging its PREDATOR™ protein engineering platform, at IMMUNOLOGYTM 2024, the annual meeting of the Ame
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).